A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

Teprotumumab

Administered as an SC injection.

Trial Locations (1)

PPD Development, LP, Las Vegas